FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291291567> ?p ?o ?g. }

• W4291291567 endingPage "S76" @default.
• W4291291567 startingPage "S76" @default.
• W4291291567 abstract "To present 11-year results from DRAMES (“Décès en Relation avec l’Abus de Médicaments Et de Substances” or Deaths in Relation with the Abuse of Drugs and Substances) study and provide new insights into deaths at therapeutic concentration for two opioid substitution treatments (OSTs): methadone (MTD) and buprenorphine (BUP). DRAMES study is an ANSM nationwide study initiated in 2005 in France. It is based on spontaneous declarations by forensic toxicologists and medical examiners of drugs of abuse related deaths in order to identify dangerous substances, assess their toxicity and monitor trends in fatalities. This database may be useful to better understand toxicity of MTD and BUP and therefore help forensic toxicologists in interpreting postmortem blood concentrations. The study included data from 2010 to 2020, from 27 laboratories in France. Drug imputability was determined cross-blinded by a forensic toxicologist and an addicto-vigilant pharmacist. A causality score from level 1 (high) to 4 (low) is assigned to each substance in connection with the occurrence of death according to the blood concentration and also making it possible to prioritize the molecules between them among those who are involved and those who are only identified. For level 1, depending on the number of molecules involved, the score breaks down into 1.0 (1 single substance), 1.1 (1 predominant substance), 1.2 (2 co-dominant substances) or 1.3 (at least 3 co-dominant substances). Monointoxication groups included 1.0 and 1.1 fatalities and polyintoxication group included 1.2 and 1.3 fatalities. Therapeutic concentrations were inferior to 200 ng/mL and inferior to 10 ng/mL for MTD and BUP, respectively. Non-parametric Mann-Whitney U tests were used to compare median concentrations between the different groups. The study included 1519 MTD-related deaths and 423 BUP-related deaths. Among those, 334 and 319 deaths were within the therapeutic range for MTD and BUP, respectively. For MTD at therapeutic concentrations, higher concentrations were observed in the monointoxication group than in the polyintoxication group (149 vs. 119 ng/mL; P < .001). But there was no difference between the naive and treated with OST groups (143 vs. 142 ng/mL; P = 0.461). Nor age, gender, association with cocaine or QTc-interval prolongation inducing drugs had a statistically significant effect on MTD concentrations. For BUP, at therapeutic concentrations, higher concentrations were observed in the monointoxication group than in the polyintoxication group (2.8 vs. 2.2 ng/mL; P = 0.048). BUP concentrations were also higher in treated with OST group than in naive ones (2.4 vs. 1.1 ng/mL; P = 0.005). This study identified different pattern for MTD and BUP fatalities at therapeutic concentration. Interestingly and contrary to BUP, at therapeutic concentrations, MTD concentrations did not differ in people under treatment and the naive ones. It has been showed that MTD induces more QTc-interval prolongation than BUP. Interindividual differences in susceptibility to cardiac toxicity could be an explanation for the deaths that could not be explained by therapeutic concentration or drug combination alone. This study identified a different pattern for BUP and MTD fatalities at therapeutic concentration, suggesting a different toxicity mechanistic for the two OSTs at these concentrations." @default.
• W4291291567 created "2022-08-14" @default.
• W4291291567 creator A5012951044 @default.
• W4291291567 creator A5025705459 @default.
• W4291291567 creator A5025741148 @default.
• W4291291567 creator A5029439758 @default.
• W4291291567 creator A5060791239 @default.
• W4291291567 creator A5062011943 @default.
• W4291291567 date "2022-09-01" @default.
• W4291291567 modified "2023-10-05" @default.
• W4291291567 title "New insights into buprenorphine and methadone related fatalities at therapeutic concentration: 11-year results from French national DRAMES study" @default.
• W4291291567 doi "https://doi.org/10.1016/j.toxac.2022.06.106" @default.
• W4291291567 hasPublicationYear "2022" @default.
• W4291291567 type Work @default.
• W4291291567 citedByCount "0" @default.
• W4291291567 crossrefType "journal-article" @default.
• W4291291567 hasAuthorship W4291291567A5012951044 @default.
• W4291291567 hasAuthorship W4291291567A5025705459 @default.
• W4291291567 hasAuthorship W4291291567A5025741148 @default.
• W4291291567 hasAuthorship W4291291567A5029439758 @default.
• W4291291567 hasAuthorship W4291291567A5060791239 @default.
• W4291291567 hasAuthorship W4291291567A5062011943 @default.
• W4291291567 hasBestOaLocation W42912915671 @default.
• W4291291567 hasConcept C118552586 @default.
• W4291291567 hasConcept C126322002 @default.
• W4291291567 hasConcept C158342456 @default.
• W4291291567 hasConcept C170493617 @default.
• W4291291567 hasConcept C185592680 @default.
• W4291291567 hasConcept C194828623 @default.
• W4291291567 hasConcept C2778767360 @default.
• W4291291567 hasConcept C2778949969 @default.
• W4291291567 hasConcept C2780035454 @default.
• W4291291567 hasConcept C2781063702 @default.
• W4291291567 hasConcept C3018481051 @default.
• W4291291567 hasConcept C40010229 @default.
• W4291291567 hasConcept C43617362 @default.
• W4291291567 hasConcept C71924100 @default.
• W4291291567 hasConcept C98274493 @default.
• W4291291567 hasConceptScore W4291291567C118552586 @default.
• W4291291567 hasConceptScore W4291291567C126322002 @default.
• W4291291567 hasConceptScore W4291291567C158342456 @default.
• W4291291567 hasConceptScore W4291291567C170493617 @default.
• W4291291567 hasConceptScore W4291291567C185592680 @default.
• W4291291567 hasConceptScore W4291291567C194828623 @default.
• W4291291567 hasConceptScore W4291291567C2778767360 @default.
• W4291291567 hasConceptScore W4291291567C2778949969 @default.
• W4291291567 hasConceptScore W4291291567C2780035454 @default.
• W4291291567 hasConceptScore W4291291567C2781063702 @default.
• W4291291567 hasConceptScore W4291291567C3018481051 @default.
• W4291291567 hasConceptScore W4291291567C40010229 @default.
• W4291291567 hasConceptScore W4291291567C43617362 @default.
• W4291291567 hasConceptScore W4291291567C71924100 @default.
• W4291291567 hasConceptScore W4291291567C98274493 @default.
• W4291291567 hasIssue "3" @default.
• W4291291567 hasLocation W42912915671 @default.
• W4291291567 hasOpenAccess W4291291567 @default.
• W4291291567 hasPrimaryLocation W42912915671 @default.
• W4291291567 hasRelatedWork W1968217097 @default.
• W4291291567 hasRelatedWork W2002091306 @default.
• W4291291567 hasRelatedWork W2026811644 @default.
• W4291291567 hasRelatedWork W2058947309 @default.
• W4291291567 hasRelatedWork W2098852732 @default.
• W4291291567 hasRelatedWork W2127569342 @default.
• W4291291567 hasRelatedWork W2160347759 @default.
• W4291291567 hasRelatedWork W3216869366 @default.
• W4291291567 hasRelatedWork W4287925734 @default.
• W4291291567 hasRelatedWork W4291291567 @default.
• W4291291567 hasVolume "34" @default.
• W4291291567 isParatext "false" @default.
• W4291291567 isRetracted "false" @default.
• W4291291567 workType "article" @default.